World News – CA – Palomar Holdings, Inc. Announces Agreement With Marsh’s Torrent Technologies For Private Flood Insurance Solutions For WYO Offer


LA JOLLA, Calif., Nov 11, 2020 / PRNewswire / – Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar” or “The Company”) for an agreement with Torrent Technologies, a company that provides services and technologies For Flood Insurance and part of Marsh, to provide Torrent’s Write-Your-Own (WYO) bus customers and their agents new and recognized private flood insurance options

Under the agreement, Palomar’s recognized residential flood insurance program, Flood Guard, will be integrated into Torrent’s state-of-the-art flood handling platform This will provide agents to WYO companies who choose more options to meet the unique flood risk needs of their clients and help bridge the flood insurance gap In the United States

Flood Guard will be the first private flood insurance option on the TorrentFlood® platform that will enable agents to sell the National Flood Insurance Program policies as well as quote, link, and issue in real time a curated list of private flood insurance options

In contrast to unacceptable policies, policies acceptable to states are regulated and supported with state guarantee funds, providing policyholders with additional protection in the event of a carrier bankruptcy

“Agents have told us that they want more flood insurance options on our platform, and in particular the recognized policy option,” said Torrent Technologies CEO Kevin Tobin. “With the addition of Flood Guard, WYO can provide their agents with more Opportunities to protect more homeowners from the number one natural hazard in the US ”

Mac Armstrong, Founder, CEO and Chairman of Palomar Specialty added: “Flood Guard is an affordable private flood insurance solution with flexible payment plans backed by the strength of the A-rated carrier. We are pleased to integrate our offerings on the Torrent platform and provide expanded opportunities for WYO companies. And its agents « 

With annual premiums as low as $ 200, Flood Guard is available on an acceptable basis in the following eleven states: AZ, CA, HI, IL, IN, NV, OK, OR, PA, SC, and UT, with more mentioned Coming up, homeowners can purchase up to $ 5 million in housing, $ 1 million in personal property, and $ 50,000 in loss coverage of use either on a primary or surplus basis.

Flood Guard is expected to be fully integrated into TorrentFlood in Q1 2021

Palomar Holdings, Inc. is a holding company of Palomar Specialty Insurance Company, Palomar Specialty Reinsurance Company Bermuda Ltd, Palomar Insurance Agency, and Palomar Excess Insurance Company and Palomar Inc. is an innovative insurance company focused on providing specialized property insurance to residential and commercial clients allowing expertise Palomar underwriting and analyzing it by focusing on specific markets that it believes are not adequately served by other insurance companies, such as the earthquake, wind and flood insurance markets. Palomar Specialty Insurance, the insurance subsidiary of Palomar, is a recognized transportation company in 31 states with an A Best Financial Strength Rating « A- » (Excellent)

Marsh is the world’s leading insurance broker and risk advisor with more than 35,000 associates operating in more than 130 countries. Marsh serves commercial and individual clients through data-based risk solutions and advisory services. Marsh is a subsidiary of Marsh & McLennan Enterprises. New York: MMC), the leading global professional services company in the areas of risk, strategy and people with annual revenues close to US $ 17 billion and 76,000 employees worldwide, MMC helps clients navigate an increasingly dynamic and complex environment through four market leaders. Follow Marsh, Guy Carpenter, Mercer, and Oliver Wyman: Twitter: MarshGlobal; Linkedin Social networking site Facebook; And YouTube, or subscribe to BRINK

The Endpoint Security Market will accelerate at a CAGR of over 17% during 2020-2024 | Volume, Engagement, Trends, Analysis and Forecasting | Research report by Technavio

Technavio monitors the home water purifier filter market as it prepares to grow by US $ 1 72 billion over the 2020-2024 period, registering progress at a compound annual growth rate of close to 8% over the forecast period. The report provides an up-to-date analysis regarding the current market scenario, latest trends, drivers and environment Total Market Download Free Sample Report on COVID-19

The COVID-19 pandemic continues to change the growth of different industries, however, the direct impact of the outbreak is diverse. While only a few industries will record a decrease in demand, many other industries will continue to be undamaged and show promising growth opportunities that COVID will have. -19 Low impact on the household water purifier filters market is likely to increase market growth in 2020 compared to market growth in 2019

Buy 1 Technavio Report and get the second at 50% off Buy 2 Technavio reports and get the third for free

The market is segmented, and retail score will accelerate during the forecast period 3M Amway Corp., EcoWater Systems LLC, Haier Smart Home Ltd., Honeywell International Corporation, KENT RO Systems Ltd, Panasonic Corporation Pentair Plc, Unilever Group and Whirlpool Corp are some of the key participants In the market Although the increase in waterborne diseases will provide tremendous growth opportunities, the availability of bottled drinking water is likely to pose a challenge for market vendors in an effort to help players consolidate their foothold in the market. This Home Water Purifier Filter Market Outlook Report provides an analysis The report also enables industry leaders with detailed information on the competitive landscape and insights into the different product offerings offered by different companies.

Technavio’s custom research reports provide detailed insights into the impact of COVID-19 at industry, regional, and subsequent supply chain operations.This personalized report will also help customers keep up with new product launches in markets related to COVID-19 direct and indirect from &, Upcoming vaccines, pipeline analysis, and significant developments in vendor operations and government regulations

To learn more about global trends affecting the future of market research, download a free sample: https: // www / talk-to-us? report = IRTNTR44710

Technavio provides a detailed market picture through the method of studying, synthesizing and collecting data from multiple sources. The Home Water Purifier Filters Market Report covers the following areas:

This study identifies technological innovations to differentiate products as one of the main reasons driving the growth of the home water purifier filters market over the next few years

Technavio proposes three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios’ in-depth research has both direct and indirect affected market research reports on COVID-19

Register for a free trial today and get instant access to 17,000 market research reports

Technavio is a global leader in technology research and consulting that focuses their research and analysis on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to improve their market positions With more than 500 professional analysts, the Technavios report library consists of more than From 17,000 reports and statistics, covering 800 technologies, spanning 50 countries, their client base is comprised of organizations of all sizes, including over 100 Fortune 500 companies This growing client base relies on comprehensive Technavios coverage, extensive research, and actionable market insights to identify opportunities. In the current and potential markets and assessing their competitive positions within changing market scenarios

Technavio Research Jesse Medamedia & Marketing Executive US: 1844364 1100UK: 44203893 3200 Email: [email protected] Website: www tknaviocom /

Ultimovacs ASA (« Ultimovacs », ULTIMO tape), a pharmaceutical company developing new immune therapies against cancer, today announced its results for the third quarter of 2020. A presentation by the company’s management team will be presented today via webcast at 09:00 Daylight Saving Time in Central Europe

The presentation can be viewed as a live webcast, and can be accessed directly through this link or through the link displayed under Reports and Presentations in the Investors section of’s website

The full report and presentation are also available as reports and presentations in the Investors section of the Ultimovacs website at

About Ultimovacs UV1 candidate universal cancer vaccine promotes the high diffusion of human telomerase (hTERT) to be effective across the dynamic stages of tumor growth and their microenvironment by directing the immune system to the hTERT antigens present in more than 80% of all cancers, UV1 directs CD4 T-helper cells to tumor with the goal of activating the immune system chain to increase anti-tumor responses The strategy of Ultimovacs is to clinically demonstrate the effect of UV1s in a group of cancers and in many immunotherapy groups as we expand our pipeline of cancer vaccine treatments, convinced that a comprehensive approach may be the key. To achieve better patient outcomes

NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 « the company), a clinical-stage nanomedicine company pioneering new approaches to cancer treatment, today announced new positive data in vivo preclinical studies from two (2) in The 35th Anniversary of the Society for Cancer Immunotherapy (SITC) ePoster presentation was made by Nanobiotix and one oral presentation was made by University of Texas MD Anderson Cancer Center

Historically, data have shown that radiation therapy can modulate the immune system. However, clinical evidence for remote tumor control and anti-tumor immunity is rare. As such, there is an opportunity for novel therapeutic solutions with the potential to trigger a robust anti-tumor response if validated. This feature could improve treatment outcomes for patients receiving treatment. Radiation alone and can also be combined with immune checkpoint inhibitors (ICIs) such as PD-1 and anti-CTLA to improve response rates and survival outcomes

NBTXR3 is a potentially first-in-class radiologic enhancer to be administered once directly into the tumor when activated by radiotherapy. The candidate product is designed to increase energy deposits within the tumor without increasing deposits in surrounding healthy tissues. This comprehensive physical work method performs this To increase the tumor killing effect along with the adaptive immune response

Modification of the TCR reference by radiotherapy-activated NBTXR3 nanoparticles Audrey Darmon, Ping Zhang, Sebastian Paris

In this study, mice with immunocompetence on both sides were injected with colon cancer cells. Intra-tumor injection of NBTXR3 or a 5% glucose solution was given to right wing tumors at 25% of the primary tumor volume. Right wing tumors were then irradiated, and left. Left wing tumors without treatment To assess the role of CD8 T cell infiltration in tumor control and sporadic effect, CD8 T cells were depleted in some mice treated with NBTXR3

The results show a similar control of the treated tumor in both the NBTXR3 activated by the radiotherapy and the glucose treatment combinations plus the radiotherapy, but only NBTXR3 that is activated by the radiotherapy produced an exogenous effect that depletion of CD8 T cells canceled the absolute effect Completely, indicating that CD8 T cells drive the NBTXR3-induced absolute effect by radiotherapy

TCR diversity analysis of NBTXR3 activated with only 3x4Gy dose of radiotherapy indicated that more TCR diversity could be found in tumors treated with NBTXR3 compared to radiotherapy alone. In addition, a significant difference in TCR diversity between treated and untreated tumors was observed. Treated in the NBTXR3 group, while no significant difference was observed in the group that received radiotherapy alone.

Immuno-radiation NBTXR3 nanoparticles improve survival and generate long-term antitumor memory in a murine lung cancer model resistant to PD1, Yoon Ho, Sebastian Paris, Hampartsum Barsomian, Chek Osita Abana, Sumel Gandhi, Quinnh No Nguyen, Maria Angelica Cortez, James W. Welsh

Although a previous study showed that treatment with high-dose radiation and NBTXR3 on primary tumors combined with a systemic antagonist PD-1 was able to improve the external effect in a metastatic lung cancer model in mice, most mice died in End due to secondary tumor growth This new study aims to evaluate the use of NBTXR3 in the primary tumor, high-dose radiotherapy in the primary tumor, low-dose radiotherapy in the secondary tumor (RadScopal „), and checkpoint inhibition in the form of anti-PD-1 and anti-CTLA- 4 To achieve full control of both primary and second tumors in mice

All mice in all groups except the group receiving NBTXR3 and RadScopal „and checkpoint inhibition together died due to primary or secondary tumor growth in NBTXR3 plus RadScopal„ plus checkpoint inhibition group, primary and secondary tumors were eliminated in 50% of mice No tumor growth was observed in these mice after metastatic lung cancer cells were reintroduced into the body.

These data show that the combination of NBTXR3, RadScopal „, and immunotherapy has been observed to significantly improve control of both primary and secondary tumors, extend survival, and reduce lung metastases in lung cancer resistant to PD-1 model. Moreover, this treatment combination has been observed to enhance the anti-tumor response at the molecular and cellular levels, and to produce long-term anti-tumor immune memory.

NBTXR3 is a new, possibly first-in-class, radioactive enhancer consisting of functional hafnium oxide nanoparticles administered by a single intra-tumor injection and activated by radiotherapy The basic mode of action (MoA) for NBTXR3 is designed to generate Increased cellular destruction when activated by radiotherapy without increasing damage to healthy tissues thus, this cellular destruction also leads to an adaptive immune response

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or pharynx in elderly patients unable to receive chemotherapy or cetuximab with limited treatment options and promising results have been observed in a phase I trial with regard to local control in The United States, the company began the regulatory process to start a phase III clinical trial in locally advanced head and neck cancers in February 2020, the FDA granted the regulatory fast-track classification for the investigation of NBTXR3 that is activated by radiotherapy, with or without cetuximab, to treat patients. Those with locally advanced squamous cell carcinoma of the head and neck not eligible for platelet chemotherapy

Nanobiotix also runs a tumor immunoassay development program.The company launched a clinical trial of NBTXR3 phase 1 that is activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in localized recurrent (LRR) or recurrent and metastasis (R / M) HNSCC re-irradiation of HN, lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy

Other ongoing NBTXR3 trials treat patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or non-resectable rectal cancer along with chemotherapy and head and neck cancer in addition to concurrent chemotherapy and pancreatic cancer The company is also involved in a comprehensive clinical research collaboration And expand with the University of Texas MD Anderson Cancer Center to expand the NBTXR3 development program

Founded in 2003, Nanobiotix is ​​a pioneer in nanomedicine in the clinical phase and a pioneer in new approaches to dramatically alter patient outcomes by bringing nanophysics to the heart of the cell

The Nanobiotix philosophy is rooted in designing ground-breaking physical approaches to deliver highly effective, scalable solutions to meet unmet medical needs and challenges

A new Nanobiotixs technology, NBTXR3, aims to extend the benefits of radiation therapy to millions of cancer patients. Nanoblotting immuno-oncology program has the potential to bring a new dimension to cancer immunotherapies

Nanobiotix is ​​listed on the regulated market for Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) The company is headquartered in Paris, France, with a US subsidiary in Cambridge, Massachusetts, and subsidiaries European countries in France, Spain and Germany

This press release contains certain forward-looking statements relating to Nanobiotix and its business, including its prospects and product candidate development. These forward-looking statements are based on assumptions that Nanobiotix considers reasonable. However, there can be no guarantee that the estimates made in such statements Forward-looking will be verified, for which the estimates are subject to numerous risks including the risks stipulated in the global registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R20-010 on May 12, 2020 (copy available at www nanobiotics com) and for development Economic conditions, financial markets and markets in which Nanobiotix operates The forward-looking statements contained in this press release are also subject to risks unknown to Nanobiotix or not currently considered as Nanobiotix material. The occurrence of all or part of these risks may lead to actual results, financial conditions or performance. Or, Nanobiotix’s accomplishments are materially different from such forward-looking statements

Ultimovacs ASA (« Ultimovacs », ULTIMO tape), a pharmaceutical company developing new immune therapies against cancer, today announced its results for the third quarter of 2020

Technavio monitors the home water purifier filter market as it braces for growth of US $ 1 72 billion

British Identity Consultants Ltd., a comprehensive provider of identity, privacy, governance and security solutions, has partnered with

NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 « the company), the clinical-stage nanomedicine company pioneering new approaches to treatment

Mobile Care Chicago received a grant of $ 5,000 from SBB Research Group, a Chicago-area investment firm that offers monthly grants

The global milling market is preparing to experience spending growth of more than US $ 1 between 2024 at CAGR

The China Yiwu Imported Commodities Fair 2020, as a professional and market-oriented trading platform for imported goods, will be held in

It’s early holiday savings season with discounts and thousands of deals from brands including Laneige, LEGO, Skip Hop and

Singapore – Media OutReach – November 6, 2020 – Logicalis Asia, part of the Logicalis Group, the leading international IT solutions and managed services

ONLYOFFICE is very multi-level and versatile, it is an open source collaborative platform and desktop platform for users at all levels, renaming and improving

Global Banking & Finance Review® is a leading financial portal and print magazine that provides news, analysis, opinions, reviews and interviews. & videos from the worlds of banking, finance, business, trade, technology, investment, brokerage, foreign exchange, taxes, & Legal, Islamic Finance, Asset & Wealth Management
Copyright © 2010-2020 GBAF Publications Ltd – All Rights Reserved

Necessary cookies are absolutely necessary for the website to function properly This category includes only cookies that ensure the basic functions and security features of the website These cookies do not store any personal information

Marsh, Flood insurance, NYSE: MMC, Marsh & McLennan Companies

World News – CA – Palomar Holdings, Inc. Announces Agreement with Marsh’s Torrent Technologies Private Flood Insurance Solutions to Offer WYO


Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: